ID   YPK-1
AC   CVCL_CZ89
DR   Wikidata; Q54995478
RX   CelloPub=CLPUB00333;
RX   PubMed=17089051;
RX   PubMed=18575732;
CC   Population: Japanese.
CC   Doubling time: 49.3 hours (CelloPub=CLPUB00333).
CC   HLA typing: A*02,24; B*01,46; C*03 (PubMed=18575732).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C8294; Pancreatic adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 10-04-25; Version: 9
//
RX   CelloPub=CLPUB00333;
RA   Yamamoto K., Yahara N., Gondo T., Ishihara T., Oka M.;
RT   "Establishment and characterization of a new human pancreatic cancer
RT   cell Line, YPK-1.";
RL   Bull. Yamaguchi Med. Sch. 49:33-42(2002).
//
RX   PubMed=17089051; DOI=10.3892/or.16.6.1285;
RA   Toshimitsu H., Iizuka N., Yamamoto K., Kawauchi S., Oga A., Furuya T.,
RA   Oka M., Sasaki K.;
RT   "Molecular features linked to the growth-inhibitory effects of
RT   gemcitabine on human pancreatic cancer cells.";
RL   Oncol. Rep. 16:1285-1291(2006).
//
RX   PubMed=18575732; DOI=10.3892/or.20.1.155;
RA   Kawaoka T., Oka M., Takashima M., Ueno T., Yamamoto K., Yahara N.,
RA   Yoshino S., Hazama S.;
RT   "Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes
RT   stimulated by the MUC1-expressing human pancreatic cancer cell line
RT   YPK-1.";
RL   Oncol. Rep. 20:155-163(2008).
//